Stay updated on Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedPage revision tag updated from v3.5.4 to v3.5.5, indicating a new build of the page. This change updates the page's metadata rather than its visible content or behavior.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe study record now displays Revision: v3.5.4, updating the document to the latest version and replacing the previous Revision: v3.5.3.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page’s displayed revision/build number was updated from v3.5.2 to v3.5.3 in just the release/version footer, without altering study information such as eligibility, treatment arms, or study outcomes.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check76 days agoChange DetectedAdded Differentiated Thyroid Carcinoma to the list of eligible tumor types for the study.SummaryDifference0.0%

- Check83 days agoChange DetectedHepatocellular carcinoma was added to the list of conditions and the location label was updated from Napoli, Italy to Naples, Italy (80131).SummaryDifference0.1%

Stay in the know with updates to Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Combo With Atezolizumab in Solid Tumors Clinical Trial page.